Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 104.53M P/E 0.61 EPS this Y 5.40% Ern Qtrly Grth -
Income -84.7M Forward P/E -1.42 EPS next Y -13.60% 50D Avg Chg -9.00%
Sales 144k PEG - EPS past 5Y - 200D Avg Chg -24.00%
Dividend N/A Price/Book 0.43 EPS next 5Y - 52W High Chg -59.00%
Recommedations 1.70 Quick Ratio 6.71 Shares Outstanding 89.64M 52W Low Chg 8.00%
Insider Own 6.65% ROA -28.22% Shares Float 74.76M Beta 1.12
Inst Own 46.12% ROE -44.62% Shares Shorted/Prior 1.93M/1.69M Price 1.18
Gross Margin - Profit Margin - Avg. Volume 1,168,453 Target Price 6.83
Oper. Margin -17,699.23% Earnings Date Oct 31 Volume 1,362,926 Change -0.84%
About Chimerix, Inc.

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Chimerix, Inc. News
11/11/24 Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
11/09/24 Chimerix Third Quarter 2024 Earnings: Misses Expectations
11/08/24 Q3 2024 Chimerix Inc Earnings Call
11/08/24 Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ...
11/07/24 Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates
11/07/24 Chimerix: Q3 Earnings Snapshot
11/07/24 Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
11/01/24 LiveOne Leads The Pack Of 3 US Penny Stocks
11/01/24 Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
10/18/24 Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/22/24 Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation
09/03/24 Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
08/14/24 Q2 2024 Chimerix Inc Earnings Call
08/13/24 Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates
08/13/24 Chimerix: Q2 Earnings Snapshot
08/13/24 Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
08/06/24 Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
07/05/24 Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/30/24 Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
05/02/24 Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call Transcript
CMRX Chatroom

User Image Johnny_Three_Sixteen Posted - 40 minutes ago

$CMRX Australia news due anytime now.

User Image JDRStuart Posted - 3 days ago

$CMRX From the one to watch on KZIA board

User Image JDRStuart Posted - 3 days ago

$CMRX

User Image lyn30 Posted - 3 days ago

$CMRX Can u pls tell me if this has has option to short? No worries I will check 😂

User Image ARDX_Bull Posted - 6 days ago

$CMRX Waiting is boring but the only game of the town! On November 14, 2024 - Vestal Point Capital, LP filed a 13F-HR form disclosing ownership of 1,400,000 shares of Chimerix valued at $1,302,000 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 14, 2024 disclosing 1,400,000 shares of Chimerix Bridgeway Capital Management Inc filed a 13F-HR form disclosing ownership of 1,065,914 shares of Chimerix valued at $991,300 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 14, 2024 disclosing 1,080,914 shares of Chimerix, Inc.. This represents a change in shares of -1.39% during the quarter. Adage Capital Partners Gp, L.l.c. filed a 13F-HR form disclosing ownership of 600,000 shares of Chimerix, Inc. (US:CMRX) valued at $558,000 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 14, 2024 disclosing 600,000 shares

User Image ARDX_Bull Posted - 6 days ago

$CMRX The management team said they’re “monitoring the listing compliance situation…” all talk no action. On November 14, 2024 - Millennium Management Llc filed a 13F-HR form disclosing ownership of 2,395,735 shares of Chimerix, Inc. (US:CMRX) valued at $2,228,034 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 14, 2024 disclosing 1,021,305 shares of Chimerix, Inc.. This represents a change in shares of 134.58% during the quarter. On November 14, 2024 - Armistice Capital, Llc filed a 13F-HR form disclosing ownership of 2,208,000 shares of Chimerix, Inc. (US:CMRX) valued at $2,053,440 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 14, 2024 disclosing 2,224,000 shares of Chimerix, Inc.. This represents a change in shares of -0.72% during the quarter.

User Image Onatarty Posted - 1 week ago

$CMRX $ALRN 🚨💥🚀🔥 PR is incoming. $BOLT.CN $.31 (+19.23%) average volume increased ~100%. I'm going to add on Monday if it's still this low. Latest News 🚀🤑 Market cap at $5.7M; Whiting’s influence may drive upward movement if new partnerships or exploration progress 1️⃣ Bolt Metals ($BOLT.CN) advances with two key updates: Ben Whiting joins as Technical Advisor, and a C$544,500 private placement closed 💸. 2️⃣ Funding: The placement includes shares and warrants, exercisable at C$0.75 for two years, with proceeds for exploration, working capital, and copper project growth ⚒️

User Image ARDX_Bull Posted - 1 week ago

$CMRX New owner On November 13, 2024 - BlackRock, Inc. filed a 13F-HR form disclosing ownership of 815,992 shares of Chimerix, Inc. (US:CMRX) valued at $758,873 USD as of September 30, 2024. And On November 12, 2024 - Acadian Asset Management Llc filed a 13F-HR form disclosing ownership of 2,188,482 shares of Chimerix, Inc. (US:CMRX) valued at $2,035,288 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 6, 2024 disclosing 2,174,813 shares of Chimerix, Inc..

User Image ARDX_Bull Posted - 1 week ago

$CMRX On November 12, 2024 - Geode Capital Management, Llc filed a 13F-HR form disclosing ownership of 846,249 shares of Chimerix, Inc. (US:CMRX) valued at $787,012 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 9, 2024 disclosing 885,824 shares of Chimerix, Inc.. This represents a change in shares of -4.47% during the quarter.

User Image SweSapiens Posted - 1 week ago

$CMRX The rocket is getting ready for launch?

User Image justiceforb_85 Posted - 1 week ago

$CMRX strong data for dordaviprone for H3 K27M-mutant DMG. I think the phase 3 will be successful, which will be amazing for the patients who have limited treatment options.

User Image CAD_CAM Posted - 1 week ago

$CMRX Chimerix’s Phase 2 Reassessment Boosts Buy Rating Amid Promising Data and Strong Financials

User Image Bigdubs Posted - 1 week ago

$CMRX sold at 1.04… I’ll be back, thanks for a nice gain.

User Image ocatraps Posted - 1 week ago

$CMRX yesterday’s conference call was embarrassing to say the least. It lasted 12 minutes, no analysts interested and just one silly question they were not even able to give a convincing answer to.

User Image ocatraps Posted - 1 week ago

$CMRX this company is a joke and it’s been played accordingly. It could go even up to 2 dollars intraday but at the end of the trading day will still be below 1. Delisting coming.

User Image ARDX_Bull Posted - 1 week ago

$CMRX https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-dabrafenib-trametinib-braf-solid-tumors#:~:text=The%20Food%20and%20Drug%20Administration,in%20a%20gene%20called%20BRAF. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma#:~:text=FDA%20approves%20atezolizumab%20for%20BRAF%20V600%20unresectable%20or%20metastatic%20melanoma,-Share&text=On%20July%2030%2C%202020%2C%20the,positive%20unresectable%20or%20metastatic%20melanoma.

User Image ARDX_Bull Posted - 1 week ago

$CMRX Mentioned this IDMC last year that was repeated both by Mike on ER and Ed White on his analytical theories for a Buy $11 PT yesterday. Now back to 2014 GSK sponsoring a ph3 trial was called off early by IDMC and patients who were on placebo unmasked and receiving all drug treatment personally i never believed it’s even fair for children to have placebo in our Ph3 Action trial. it’s inhumane. https://cancerletter.com/clinical/20140731_2/

User Image Big_Dzick Posted - 1 week ago

$CMRX will go up to 2

User Image jiggs10 Posted - 1 week ago

$CMRX I think there will be some bio Buyouts over the long weekend

User Image jiggs10 Posted - 1 week ago

$CMRX They have a pretty good drug n tons of cash. Their obviously on the chopping block at $6 to $10

User Image ARDX_Bull Posted - 1 week ago

$CMRX Big holder is still here On November 7, 2024 - Monaco Asset Management SAM filed a 13F-HR form disclosing ownership of 4,221,574 shares of Chimerix, Inc. (US:CMRX) valued at $3,926,064 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 7, 2024 disclosing 4,377,674 shares of Chimerix, Inc.. This represents a change in shares of -3.57% during the quarter. So as this smaller one On November 6, 2024 - Acuitas Investments, LLC filed a 13F-HR form disclosing ownership of 796,401 shares of Chimerix, Inc. (US:CMRX) valued at $740,653 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 5, 2024 disclosing 638,657 shares of Chimerix, Inc.. This represents a change in shares of 24.70% during the quarter.

User Image ARDX_Bull Posted - 1 week ago

$CMRX Edward White has given his Buy rating price at $11 due to a combination of factors surrounding Chimerix’s ongoing developments and financial health. .... Chimerix’s Phase 3 ACTION study, which involves the drug dordaviprone for treating H3 K27M-mutant glioma, has been progressing positively. The Independent Data Monitoring Committee has recommended the continuation of the study following a safety review. This study is significant as dordaviprone has FDA Fast Track and Rare Pediatric Disease Designations, highlighting its potential importance in treating high-grade glioma. The expectation of interim overall survival data in the third quarter of 2025 and the potential for accelerated FDA approval based on progression-free survival data further support the Buy rating, as these developments could lead to a successful drug launch by late 2026.

User Image ocatraps Posted - 1 week ago

$CMRX what a surprise, everything is up and this pos is tanking….

User Image lecorb Posted - 2 weeks ago

$CMRX Chimerix GAAP EPS of -$0.26 misses by $0.02, revenue of $0.02M misses by $0.29M

User Image Estimize Posted - 2 weeks ago

$CMRX reported - EPS and - revenue for Q3. http://www.estimize.com/intro/cmrx?chart=historical&metric_name=eps&utm_content=CMRX&utm_medium=

User Image SomePoorGuy Posted - 2 weeks ago

$CMRX Quarterly Financials won't mean much, but a solid update on the ONC206 dose escalation study would be great.

User Image rexston Posted - 2 weeks ago

$CMRX why drop 10%?

User Image Bartos1976 Posted - 2 weeks ago

$CMRX letting this one ride for the long haul

User Image ManfredMustermann Posted - 2 weeks ago

$CMRX up by small volume

User Image MCC2ZAP Posted - 2 weeks ago

$CMRX UK detects two more cases of MPOX variant.

Analyst Ratings
HC Wainwright & Co. Buy Aug 14, 24
HC Wainwright & Co. Buy Mar 1, 24
Wedbush Outperform Aug 17, 23
HC Wainwright & Co. Buy Aug 16, 23
HC Wainwright & Co. Buy Aug 4, 23
Baird Outperform May 23, 23
HC Wainwright & Co. Buy May 5, 23
HC Wainwright & Co. Buy Mar 3, 23
Capital One Overweight Sep 7, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MIDDLETON FRED A Director Director Nov 17 Buy 0.9553 17,295 16,522 100,000 11/20/23
Andriole Michael T. Chief Business Offic.. Chief Business Officer and CFO May 18 Buy 1.1441 51,700 59,150 357,015 05/19/23
DEMSKI MARTHA J Director Director May 10 Buy 1.11 18,000 19,980 72,055 05/11/23
Meyer Robert J. Director Director May 08 Buy 1.14 8,750 9,975 35,150 05/10/23
MIDDLETON FRED A Director Director Mar 28 Buy 1.2076 20,000 24,152 60,000 03/29/23
Jakeman David Principal Accounting.. Principal Accounting Officer Jan 26 Sell 1.7605 3,230 5,686 136,752 01/26/23
MIDDLETON FRED A Director Director Sep 29 Buy 1.8588 20,000 37,176 40,000 10/03/22
Jakeman David Principal Accounting.. Principal Accounting Officer Sep 29 Sell 1.8603 4,400 8,185 127,532 09/30/22
Andriole Michael T. Chief Business Offic.. Chief Business Officer and CFO Aug 25 Option 2.09 50,000 104,500 262,724 08/29/22
Sherman Michael A. Chief Executive Offi.. Chief Executive Officer Jul 25 Option 2.09 100,000 209,000 125,364 07/27/22
MIDDLETON FRED A Director Director May 19 Buy 2.0369 20,000 40,738 20,000 05/20/22
Meyer Robert J. Director Director May 19 Buy 2.06 11,400 23,484 26,400 05/20/22
Andriole Michael T. Chief Business Offic.. Chief Business Officer and CFO May 17 Buy 1.709 15,000 25,635 212,724 05/18/22
DEMSKI MARTHA J Director Director May 17 Buy 1.61 10,000 16,100 54,055 05/17/22
Jakeman David Principal Accounting.. Principal Accounting Officer Feb 04 Sell 5.5622 3,300 18,355 117,666 02/04/22